Dimerix (ASX:DXB) releases positive results from Phase 2 Trial of DMX-200

Dimerix (ASX:DXB) is a clinical stage Australian Biotechnology company developing and commercialising novel drug therapies targeted at unmet patient needs, with the lead phase II clinical program (DMX-200) targeting chronic kidney disease. The company has recently announced “positive safety and efficacy data” following the company’s 27 patient Phase 2a Proof of Concept.

KEY TAKEAWAYS: 

• Phase 2a of clinical trial tests has meet the primary safety checklist and demonstrates the efficacy in a number of patients.
• 25% of patients achieved a greater than 50% reduction in proteinuria.
• 45% of patients attained the permission to continue ongoing treatment.
• Study data informs dosing of patients and targeting parameters to progress the DMX-200 Phase 2b study during 2017.

Associate Professor David Packham* , one of the Principal Investigators in the study and Director of the Melbourne Renal Research Group, said “These are very encouraging data. DMX-200, and its combination with existing best therapy, appears safe and was well tolerated. An incremental 50% fall in proteinuria is a ‘high bar’ to set in studies of this type and the observation of this efficacy endpoint in 25% of the patients certainly warrants further clinical investigation in a larger, more targeted, population.’

Dimerix CEO Kathy Harrison said, “We are delighted that this study has resulted in such positive outcomes. The clinically meaningful reductions in proteinuria are highly encouraging and support the rationale behind the program. Given this is a “hard to treat” patient group, we now have a very strong indication that the treatment is having a significant impact in slowing the progression of Chronic Kidney Disease.

More Information

Request Information